Severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review
Abstract
Background: Chronic myeloid leukaemia is a clonal myeloproliferative disorder of myeloid progenitor cells. The availability of moleculartargeted therapy with tyrosine kinase inhibitors has changed the course and treatment for patients with chronic myeloid leukemia. The long-term follow-up of adverse events amongst the kinase inhibitors played role in forming decision-making algorithms for the use of this highly effective group of therapeutics. Patients and methods: In this paper, four CML patients are presented, treated with different tyrosine kinase inhibitors. Haematologic toxicity of kinase inhibitors is the most frequent adverse effect; however, non-haematological adverse effects should also not be neglected. Conclusions: Tyrosine kinase inhibitors have changed the therapy of CML, the treatment of these patients is a long-term process. Therefore, to know adverse effects is the matter of great importance in order to promptly recognise them and treat them properly.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
